Determining thyroid I-131 effective half-life for the treatment planning of Graves' disease
Carregando...
Citações na Scopus
10
Tipo de produção
article
Data de publicação
2013
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
Autores
TRAINO, Antonio C.
Citação
MEDICAL PHYSICS, v.40, n.2, article ID 22502, 5p, 2013
Resumo
Purpose: Thyroid I-131 effective half-life (T-eff) is an essential parameter in patient therapy when accurate radiation dose is desirable for producing an intended therapeutic outcome. Multiple I-131 uptake measurements and resources from patients themselves and from nuclear medicine facilities are requisites for determining T-eff, these being limiting factors when implementing the treatment planning of Graves' disease (GD) in radionuclide therapy. With the aim of optimizing this process, this study presents a practical, propitious, and accurate method of determining T-eff for dosimetric purposes. Methods: A total of 50 patients with GD were included in this prospective study. Thyroidal I-131 uptake was measured at 2-h, 6-h, 24-h, 48-h, 96-h, and 220-h postradioiodine administration. T-eff was calculated by considering sets of two measured points (24-48-h, 24-96-h, and 24-220-h), sets of three (24-48-96-h, 24-48-220-h, and 24-96-220-h), and sets of four (24-48-96-220-h). Results: When considering all the measured points, the representative T-eff for all the patients was 6.95 (+/- 0.81) days, whereas when using such sets of points as (24-220-h), (24-96-220-h), and (24-48-220-h), this was 6.85 (+/- 0.81), 6.90 (+/- 0.81), and 6.95 (+/- 0.81) days, respectively. According to the mean deviations 2.2 (+/- 2.4)%, 2.1 (+/- 2.0)%, and 0.04 (+/- 0.09)% found in T-eff, calculated based on all the measured points in time, and with methods using the (24-220-h), (24-48-220-h), and (24-96-220-h) sets, respectively, no meaningful statistical difference was noted among the three methods (p > 0.500, t test). Conclusions: T-eff obtained from only two thyroid I-131 uptakes measured at 24-h and 220-h, besides proving to be sufficient, accurate enough, and easily applicable, attributes additional major cost-benefits for patients, and facilitates the application of the method for dosimetric purposes in the treatment planning of Graves' disease. (c) 2013 American Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4788660]
Palavras-chave
Graves' disease, I-131 effective half-life, therapy planning
Referências
- Aktay R, 1996, J NUCL MED, V37, P1815
- Berg GEB, 1996, J NUCL MED, V37, P228
- Dunkelmann S, 2007, EUR J NUCL MED MOL I, V34, P228, DOI 10.1007/s00259-006-0234-z
- Jonsson H, 2004, RADIAT PROT DOSIM, V108, P107, DOI 10.1093/rpd/nch013
- Kobe C, 2010, NUCL MED COMMUN, V31, P201, DOI 10.1097/MNM.0b013e328333d303
- Loevinger R., 1991, MIRD PRIMER ABSORBED
- Mathieu I, 1999, HEALTH PHYS, V76, P129, DOI 10.1097/00004032-199902000-00004
- Pant G. S., 2001, J MED PHYS, V26, P66
- Reinhardt MJ, 2002, EUR J NUCL MED MOL I, V29, P480, DOI 10.1007/s00259-001-0722-0
- Siantar CLH, 2002, CANCER BIOTHER RADIO, V17, P267
- Stabin MG, 2011, J NUCL MED, V52, P1156, DOI 10.2967/jnumed.111.088666
- Thomas SR, 2002, CANCER BIOTHER RADIO, V17, P71, DOI 10.1089/10849780252824091
- Traino AC, 2010, PHYS MEDICA, V26, P71, DOI 10.1016/j.ejmp.2009.08.003
- Traino AC, 2009, MED PHYS, V36, P1212, DOI 10.1118/1.3093237